Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q3 2020 · 10-Q
Revenue$1.38M$1.38M+57.5% vs Q3 2019 Net Income-$1.72M-$1.72MN/M vs Q3 2019 EPS Diluted-$0.10-$0.10N/M vs Q3 2019 Operating Income-$1,758,505N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-127.6%+302.2 pt vs Q3 2019
Net margin-124.6%+175.8 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 12, 2020 · 43 d after period end